Spyre Therapeutics, Inc. - 8-K Filing
On May 29, 2026, Spyre Therapeutics entered into the First Amendment to its Amended and Restated License Agreement with Paragon Therapeutics. The amendment expanded the definition of 'Field' from inflammatory bowel disease to all therapeutic uses but imposed restrictions: no clinical dosing for indications outside this area until June 1, 2028 (combination therapies) or 2030 (monotherapies). Restrictions may also terminate earlier if a material transaction occurs. (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $SYRE